Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the ...

While there are several immunotherapies in development for mesothelioma the Opdivo and ... Opdivo monotherapy and Merck & Co’s Keytruda (pembrolizumab) are also in clinical development.

The combination of NUC-3373 plus pembrolizumab was generally well tolerated ... Module 2 included 4 patients with non-small cell lung cancer (NSCLC) or pleural mesothelioma who had disease progression ...

Keytruda (pembrolizumab) is a prescription drug ... This includes: Malignant pleural mesothelioma: Keytruda is prescribed to adults as a first-choice treatment for malignant pleural mesothelioma ...

The Institute of Cancer Research, London, has criticised the decision by NICE not to recommend the immunotherapy, pembrolizumab, as a first-line treatment for patients with advanced head and neck ...

Pembrolizumab plus chemotherapy improves disease-free survival (DFS) in patients with high-risk endometrial cancer after surgery with curative intent, according to a study published online Oct. 16 ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless ...

PT886 is currently being evaluated as monotherapy and in combination with pembrolizumab, or with chemotherapy, either alone or in combination with pembrolizumab. The multi-center Phase I/II ...

“Based on our strong phase 2 clinical data reported previously for petosemtamab in HNSCC both as monotherapy and in combination with pembrolizumab, I continue to be confident that petosemtamab ...

Get detailed information on Pembrolizumab, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated prescription ...

The combination of NUC-3373 plus pembrolizumab was generally well tolerated ... Module 2 included 4 patients with non-small cell lung cancer or pleural mesothelioma who had disease progression on, or ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved two new indications for KEYTRUDA ® (pembrolizumab), Merck ...